Doctors have described two cases of acute psychiatric disorders in men who abruptly stopped tirzepatide injections, urging colleagues to consider this risk in vulnerable patients, infohub.kz reports.
Both patients were hospitalized with severe psychiatric symptoms — psychosis and a manic episode — after abruptly discontinuing tirzepatide (sold under the brand names Mounjaro and Zepbound), a drug in the glucagon-like peptide-1 (GLP-1) receptor agonist class. The clinical observations were published in the peer-reviewed medical journal The Primary Care Companion for CNS Disorders, ScienceAlert writes.
The first patient was a 61-year-old man admitted to hospital in October 2025 with worsening confusion, paranoia, auditory and visual hallucinations, and the rare Cotard syndrome, in which a person believes they have died or lost parts of their body. He had stopped taking tirzepatide in August of that year because of nausea.
The second patient was a 52-year-old man who arrived at the clinic the same month with mood swings, grandiose mania, impulsivity and incoherent speech. A month earlier he had abruptly discontinued the drug, having lost 45 kilograms over six months. The second patient was also found to have a vitamin B12 deficiency and increased cannabis use before hospitalization.
The report's authors stressed that these cases do not prove a direct causal link, especially since both men had previously been diagnosed with depression and anxiety disorder. However, GLP-1 receptors are present in the brain, and a European database had previously recorded 481 reports of psychiatric disorders associated with semaglutide, liraglutide and tirzepatide. The researchers note that abrupt withdrawal of such drugs may trigger acute symptoms in at-risk patients, including people with nutritional deficiencies.


